The immune-centric revolution translated into clinical application: peripheral blood mononuclear cell (pbmnc) therapy in diabetic patients with no-option critical limb-threatening ischemia (no-clti)—rationale and meta-analysis of observational studies

HIGHLIGHTS

• What: The aim of this review is to analyze the physio-pathological rationale behind the PBMNC autologous cell therapy to treat diabetic patients with CLTI, as presented in Part I. Pain was reported as an endpoint value (no Five between and four studies reported information TcPO2 and data on differences th endpoint and the baseline were available)on with a mean pain of_(measured a 10-point visual analogI2:85%). scale)
• Who: Laura Rehak et al. from the Department of Biomedicine and Prevention, Diabetes-Endocrine Section CTO Hospital, Tor Vergata Department of Diabetology Azienda Ospedaliera . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.